Business Wire

ALCON

15.12.2021 17:27:08 CET | Business Wire | Press release

Share
Alcon Continues Its Successful Rollout of PRECISION1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, continues its successful rollout of PRECISION1TM . The spherical lens is now available in key markets throughout Latin America and Asia, and PRECISION1 for Astigmatism is available in markets throughout Europe. PRECISION1 for Astigmatism and PRECISION1 sphere are also available throughout North America.

PRECISION1 contact lenses are designed to address the common reasons why 20% of new wearers drop out in the first three weeks: poor vision, poor comfort and handling issues.3 The lenses provide precise vision, long-lasting comfort and ease of handling to allow new wearers,1 especially those with long busy days, an exceptional lens-wearing experience.

Inspired from the water gradient lens material in DAILIES TOTAL1® , PRECISION1 is the first-and-only contact lens with Alcon’s proprietary SMARTSURFACE® Technology. This features a permanent, micro-thin, high-performance layer of moisture at the lens surface that helps support a stable tear film.4

A stable tear film is vital to visual performance and comfort, especially for contact lens wearers.5

“Reinforcing our mission to help people see brilliantly, we are proud of the PRECISION1 contact lens launch, designed for people with an on-the-go lifestyle, in many markets across the globe,” said Antoine Delgrange, Alcon Vice President for Vision Care International Marketing. “We understand the consumer journey can be challenging; so, as an added benefit, we are offering the opportunity for our customers to provide their new lens wearers with an exclusive activation program to make their introduction to contact lenses easy and enjoyable. The program includes resources to increase consumer confidence with their new lenses.”

“I think of PRECISION1 as the contact lens of the future. It’s so comfortable to wear and easy to fit that the wearing experience amazes my patients,” said Dr. Teodoro Tarud, optician and owner of Centro Óptico de la Costa, Columbia.*

The launch of PRECISION1 for Astigmatism provides a significant opportunity to attract new contact lens wearers. Studies show that 41% of patients have astigmatism that needs correction,6 but only 10% wear toric contact lenses.7 "Our patients love the comfort of PRECISION1! This is the best launch I have ever seen. We can fit more patient types now that toric and minus lenses are available," said Fiona Kavanagh, owner and optician at Jennings Opticians, Ireland.**

“We are committed to providing eye care professionals (ECPs) with a comprehensive portfolio of lens-wearing options based on the specific needs of their patients,” said Cheryl Donnelly, International Head of Professional Affairs at Alcon. “Now, with PRECISION1 and PRECISION1 for Astigmatism, ECPs and optical retailers can offer more lens wearers a next-generation contact lens with exceptional all-day performance.”

For more information, visit PRECISION1® One-Day Contact Lenses | PRECISION1® (myalcon.com)

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com .

* Teodoro Tarud is a paid Alcon consultant.

** Fiona Kavanagh is a paid Alcon consultant.

References

  1. Grant T, Tang A. A Survey of contact lens wearers and eye care professionals on satisfaction with a new smartsurface silicone hydrogel daily disposable contact lens. Clin Optom 2020;12:9–15.
  2. In a clinical study, wherein subjects were fitted with PRECISION1 for Astigmatism contact lenses (N=78 eyes); Alcon data on file, 2020.
  3. Sulley A, Young G, Hunt C, et al. Retention rates in new contact lens wearers. Eye & Contact Lens. 2018;44:S273-S282.
  4. In vitro analysis of verofilcon A contact lenses for surface properties; Alcon data on file 2019.
  5. Craig JP, Willcox MDP, Argueso P, et al. The TFOS international workshop on contact lens discomfort: Report of the contact lens interactions with tear film subcommittee. Invest Ophthalmol Vis Sci. 2013; 54:TFOS123-TFOS156.
  6. Luensmann D, Schaeffer J, Rumney N, et al. Spectacle prescriptions review to determine prevalence of ametropia and coverage of frequent replacement soft toric contact lenses. Contact Lens and Anterior Eye ; 2018; 41 (5); 412-420.
  7. Multi-Sponsor Surveys 2014 Gallup target market report.

Connect with us on

Facebook
LinkedIn

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release

The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M

3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release

Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst

Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release

Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the

ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release

Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re

Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release

Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye